Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OmnImmune,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : TC BioPharm
Deal Size : Undisclosed
Deal Type : Partnership
CareDx, TC BioPharm Partner on AlloCell Monitoring for Cell Therapy Trial
Details : The partnership aims to support ACHIEVE clinical trial using AlloCell to evaluate the efficacy and effectiveness of TCB008, an allogeneic gamma-delta T-cell therapy for patients with AML or MDS.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : OmnImmune,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : TC BioPharm
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Mycophenolate Mofetil,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KidneyCare Immuno-optimization in Renal Allografts (KIRA)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : Mycophenolate Mofetil,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tegoprubart,Inapplicable
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Eledon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
CareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement
Details : Collaboration agreement provides Eledon with access to CareDx’s best-in-class technologies, including the study to evaluate the safety, efficacy and pharmacokinetics of AT-1501 in de novo kidney transplant recipients.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 19, 2021
Lead Product(s) : Tegoprubart,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Eledon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Mycophenolate Mofetil,Mycophenolic Acid,Azathioprine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Recipient : University of California, Davis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 29, 2021
Lead Product(s) : Mycophenolate Mofetil,Mycophenolic Acid,Azathioprine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Recipient : University of California, Davis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tegoprubart,Inapplicable
Therapeutic Area : Immunology
Study Phase : Phase I
Recipient : Eledon Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Presentation to focus on potential use of AT-1501 in kidney transplantation as well as research collaboration between Eledon and CareDx to help assess the efficacy of Eledon’s investigational AT-1501 for the prevention of rejection in upcoming kidney t...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 11, 2021
Lead Product(s) : Tegoprubart,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : Eledon Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VIR-7831,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Vir Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
CareDx Supports Vir Biotechnology’s Clinical Trial Recruitment Efforts for COMET-ICE
Details : The ongoing trial is evaluating VIR-7831, a fully human anti-SARS-CoV-2 monoclonal antibody, for the early treatment of COVID-19 in adults at high risk of hospitalization.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 23, 2021
Lead Product(s) : VIR-7831,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Vir Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Belatacept,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : UT Southwestern Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 08, 2021
Lead Product(s) : Belatacept,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : UT Southwestern Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable